

ORIGINAL ARTICLE

Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice

Niu Shi,^{1,2} Nobuhiko Hiraga,^{1,2} Michio Imamura,^{1,2} C Nelson Hayes,^{1,2} Yizhou Zhang,^{1,2} Keiichi Kosaka,^{1,2} Akihito Okazaki,^{1,2} Eisuke Murakami,^{1,2} Masataka Tsuge,^{1,2} Hiromi Abe,^{1,2} Hiroshi Aikata,^{1,2} Shoichi Takahashi,^{1,2} Hidenori Ochi,^{2,3} Chise Tatenomukai,^{2,4} Katsutoshi Yoshizato,^{2,4} Hirotaka Matsui,⁵ Akinori Kanai,⁶ Toshiya Inaba,⁵ Fiona McPhee,⁷ Min Gao,⁷ Kazuaki Chayama^{1,2,3}

¹Department of Gastroenterology and Metabolism, Applied Life Sciences, Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

²Liver Research Project Center, Hiroshima University, Hiroshima, Japan

³Laboratory for Digestive Diseases, Center for Genomic Medicine, The Institute of Physical and Chemical Research (RIKEN), Hiroshima, Japan

⁴PhoenixBio Co., Ltd., Higashihiroshima, Japan

⁵Department of Molecular Oncology and Leukemia Program Project, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

⁶Radiation Research Center for Frontier Science, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan

⁷Bristol-Myers Squibb, Research and Development, Wallingford, Connecticut, USA

Correspondence to

Professor Kazuaki Chayama, Department of Gastroenterology and Metabolism, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan; chayama@mba.ocn.ne.jp

Received 29 March 2012

Revised 18 December 2012

Accepted 20 December 2012

Published Online First

15 January 2013

ABSTRACT

Objective We recently demonstrated that combination treatment with NS3 protease and NS5B polymerase inhibitors succeeded in eradicating the virus in genotype 1b hepatitis C virus (HCV)-infected mice. In this study, we investigated the effect of combining an NS5A replication complex inhibitor (RCI) with either NS3 protease or NS5B inhibitors on elimination of HCV genotypes 1b, 2a and 2b.

Design The effects of Bristol-Myers Squibb (BMS)-605339 (NS3 protease inhibitor; PI), BMS-788329 (NS5A RCI) and BMS-821095 (NS5B non-nucleoside analogue inhibitor) on HCV genotypes 1b and 2a were examined using subgenomic HCV replicon cells. HCV genotype 1b, 2a or 2b-infected human hepatocyte chimeric mice were also treated with BMS-605339, BMS-788329 or BMS-821095 alone or in combination with two of the drugs for 4 weeks. Genotypic analysis of viral sequences was achieved by direct and ultra-deep sequencing.

Results Anti-HCV effects of BMS-605339 and BMS-821095 were more potent against genotype 1b than against genotype 2a. In in-vivo experiments, viral breakthrough due to the development of a high prevalence of drug-resistant variants was observed in mice treated with BMS-605339, BMS-788329 and BMS-821095 in monotherapy. In contrast to monotherapy, 4 weeks of combination therapy with the NS5A RCI and either NS3 PI or NS5B inhibitor succeeded in completely eradicating the virus in genotype 1b HCV-infected mice. Conversely, these combination therapies failed to eradicate the virus in mice infected with HCV genotypes 2a or 2b.

Conclusions These oral combination therapies may serve as a Peg-alfa-free treatment for patients chronically infected with HCV genotype 1b.

INTRODUCTION

Hepatitis C virus (HCV) infection is a major cause of chronic liver diseases, such as cirrhosis and hepatocellular carcinoma.^{1,2} A number of new selective inhibitors of HCV proteins, termed direct-acting antiviral agents (DAA), are currently under development. HCV inhibitors targeting NS3 protease and NS5A and NS5B polymerase activity have proceeded to clinical trials for HCV-infected

Significance of this study

What is already known on this subject?

- ▶ Anti-HCV drug monotherapy for chronic hepatitis C patients often results in viral breakthrough due to the emergence of drug-resistant clones.
- ▶ Combination treatment of NS3 PI and NS5A inhibitor can eradicate genotype 1b HCV in chronic hepatitis C patients without interferon.

What are the new findings?

- ▶ Combination treatment of NS5A inhibitor with either NS3 PI or NS5B inhibitor can eradicate HCV, but the effect differs among HCV genotypes.

How might it impact on clinical practice in the foreseeable future?

- ▶ Short-term combination of NS5A inhibitor with either NS3 PI or NS5B inhibitor might provide an effective interferon-free treatment for genotype 1b chronic hepatitis C patients; however, the combination treatment might be less effective against genotype 2.

patients. DAA are used in combination with Peg-alfa and ribavirin because monotherapy with these drugs results in the early emergence of drug-resistant variants.^{3,4} As Peg-alfa/ribavirin treatment is frequently associated with serious adverse events, an oral Peg-alfa/ribavirin-free DAA combination therapy would offer an ideal treatment option for chronic hepatitis C patients. The first proof-of-concept study to combine NS3 protease and NS5B inhibitors (INFORM-1) reported that 13 days of this combination treatment achieved robust antiviral suppression in genotype 1 HCV-infected patients, and no evidence of resistance to either compound was observed.⁵ Following the INFORM-1 study, we and other groups have also reported that a DAA-only combination comprising NS3 protease inhibitor (PI), Bristol-Myers Squibb (BMS)-650032 (asunaprevir) and NS5A replication complex inhibitor (RCI), BMS-790052 (daclatasvir) can achieve high sustained virological

response (SVR) rates in patients with HCV genotype 1b infection.⁶ A number of DAA-only combination studies are now entering phase 2 clinical trials.⁷ The effect of telaprevir was recently analysed in genotype 2 HCV-infected patients. Fifteen days of telaprevir monotherapy decreased the serum HCV RNA titre by 3.7 log₁₀ IU/ml, and 3 months of telaprevir plus 24 weeks of Peg-alfa/ribavirin triple therapy resulted in SVR in 100% of genotype 2 HCV-infected patients.⁸ However, the effect of Peg-alfa/ribavirin-free DAA combination therapy on genotype 2 HCV has not been reported.

The immunodeficient urokinase-type plasminogen activator (uPA) mouse permits repopulation of the liver with human hepatocytes that can be infected with HCV.⁹ This animal model is useful for evaluating anti-HCV drugs such as Peg-alfa and NS3 PI.^{10–11} Using this animal model, we recently described the successful elimination of HCV genotype 1b by treatment with a combination of NS3 protease and NS5B inhibitors.¹² In this study, we investigated whether short-term combination treatments with NS5A RCI and either NS3 protease or NS5B site I inhibitors could eliminate HCV *in vivo* in human hepatocyte chimeric mice, and we compared the efficacy of the drugs against HCV genotype 1 versus genotype 2.

METHODS

Compounds and cells

BMS-605339 (NS3 PI, analogue of asunaprevir), BMS-788329 (NS5A RCI, analogue of daclatasvir) and BMS-821095 (NS5B non-nucleoside analogue inhibitor; NNI) were synthesised by BMS. Huh-7 cells that stably maintain HCV replicons were propagated as subconfluent monolayers in Dulbecco's modified essential medium containing 10% fetal bovine serum, 2 mM L-glutamine, and 0.5 mg/ml geneticin (G418; Invitrogen Corp., Carlsbad, California, USA) at 37°C under 5% carbon dioxide.¹³

Determination of IC₅₀ in culture systems

The genotype 1b (Con 1) replicon cell line was constructed as described previously.¹⁴ A genotype 2a (JFH-1) cell line was generated by introducing the JFH-1 sequence from NS3 to NS5B into the genotype 1b (Con 1) backbone.¹⁵ Inhibition of HCV RNA replication by either BMS-605339, BMS-788329 or BMS-821095 for 72 h was monitored using a luciferase reporter assay. Antiviral activities of the compounds, for example, the 50% inhibitory concentration (IC₅₀), were determined as described previously.¹⁶

Human serum samples

Human serum containing a high titre of HCV genotypes 1b, 2a and 2b was obtained from patients with chronic hepatitis who had given written informed consent to participate in the study. Serum samples were divided into small aliquots and stored in liquid nitrogen until use. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved a priori by the institutional review committee.

Animal treatment

Generation of the uPA^{+/+}/SCID^{+/+} mice and transplantation of human hepatocytes were performed as described previously.¹⁷ All mice were transplanted with frozen human hepatocytes obtained from the same donor. All animal protocols described in this study were performed in accordance with the guidelines of the local committee for animal experiments, and all animals received humane care. Infection, extraction of serum samples and killing of animals were performed under ether anaesthesia. Eight weeks after hepatocyte

transplantation, mice were injected intravenously with 100 µl of HCV-positive human serum samples. Mice serum samples were obtained every 1 or 2 weeks after HCV infection, and HCV RNA levels were measured.

Treatment of HCV-infected mice with anti-HCV inhibitors

Eight weeks after HCV infection when the mice developed stable viraemia (6–8 log₁₀ copies/ml), mice were administered orally with one of the following: 75 mg/kg of BMS-605339 (twice a day); 10 or 30 mg/kg of BMS-788329 (once a day); or 30 or 100 mg/kg of BMS-821095 (once a day) for 4 weeks. To analyse the effect of the combination treatment, BMS-788329 was mixed with either BMS-605339 or BMS-821095 and given together as a cocktail. To analyse susceptibility to Peg-alfa, 10 µg/kg of human Peg-alfa (Chugai Pharmaceutical Co. Ltd., Tokyo, Japan) were administered by intramuscular injection twice a week for weeks.

RNA extraction and amplification

RNA extraction, nested PCR and quantitation of HCV by real-time PCR were performed as described previously.^{11–12} Briefly, RNA was extracted from serum samples and extracted livers using SepaGene RVR (Sankojunyaku, Tokyo, Japan) and reverse transcribed with a random hexamer and a reverse transcriptase (ReverTraAce; TOYOBO, Osaka, Japan) according to the instructions provided by the manufacturer. Quantitation of HCV complementary DNA was performed using a light cycler (Roche Diagnostic, Japan, Tokyo). The lower detection limit of real-time PCR is 3 log₁₀ copies/ml.

Sequence analysis

The nucleotide and amino acid sequences of the NS3, NS5A and NS5B regions of HCV were determined by direct sequencing as described previously.¹² The primers used to amplify the NS3 region were 5'-GTGCTCCAAGCTGGCATAAC-3' and 5'-AGGACCGAGGAATCGAACAT-3' as the first (outer) primer pair and 5'-CTAGAGTCCCCTACTTCGTG-3' and 5'-ACTGATCCTGGAGGCGTAGC-3' as the second (inner) primer pair. The primers used to amplify the NS5A region were 5'-GAA TGCAGCTCGCCGAGCAA-3' and 5'-CCATGTTGTGGTGGC GCAGC-3' as the first (outer) primer pair and 5'-GCAGCT GTTGGCAGCATAGGTC-3' and 5'-GATGGTAGTGCATGTCG CC-3' as the second (inner) primer pair. The primers used to amplify the NS5B region were 5'-TAAGCGAGGAGGCTGG TGAG-3' and 5'-CCTATTGGCCTGGAGTGTTT-3' as the first (outer) primer pair and 5'-GACTCAACGGTCACTGAGAG-3' and 5'-CCTATTGGCCTGGAGTGTTT-3' as the second (inner) primer pair. The amplified DNA fragments were separated onto a 2% agarose gel and purified using the QIAquick gel extraction kit (Qiagen, Hilden, Germany). Nucleotide sequences were determined using BigDye Terminator v3.1 cycle sequencing kit (Applied Biosystems Inc., California, USA). The obtained nucleotide and amino acid sequences were compared with the prototype sequences of genotype 1b HCV-J (GenBank accession no.: D90208)¹⁸.

Ultra-deep sequencing

We have adapted multiplex sequencing by synthesis to sequence multiple genomes simultaneously using the Illumina genome analyser. Briefly, cDNA was fragmented using sonication, and the resultant fragment distribution was assessed using the Agilent BioAnalyzer 2100 platform. A library was prepared using the Multiplexing sample preparation kit (Illumina Inc., California, USA). Imaging analysis and base

calling were performed using Illumina Pipeline software with default settings. The N-terminal 1344 nucleotides of NS3 protease, 1146 nucleotides of NS5A RCI and 1133 nucleotides of NS5B polymerase were analysed. This technique revealed an average coverage depth of over 1000 sequence reads per base pair in the unique regions of the genome. Read mapping to a reference sequence was performed using BWA.¹⁹ Direct sequencing consensus data were used to improve alignment to the reference sequence. Codon counts were merged and analysed using R V2.14.

Statistical analysis

Mice serum HCV RNA titres were compared using the Mann–Whitney U test. A p value less than 0.05 was considered statistically significant.

RESULTS

Antiviral activities of BMS-605339, BMS-788329 and BMS-821095 in cell culture systems

The inhibitory effects of BMS-605339, BMS-788329 and BMS-821095 on HCV replication were analysed *in vitro* using HCV replicon cells (genotype 1b, Con 1 and genotype 2a, JFH1). A summary of the IC₅₀ values for each drug is shown in table 1. Antiviral activities of BMS-605339 and BMS-788329 were similar to asunaprevir¹⁵ and daclatasvir,²⁰ respectively. BMS-605339 and BMS-821095 IC₅₀ values were 23-fold and 116-fold more potent against genotype 1b than against genotype 2a, respectively.

Peg-alfa treatment on mice infected with HCV genotypes 1 and 2

We first analysed the effect of Peg-alfa on mice infected with HCV genotypes 1 and 2. Mice were injected with 10⁵ copies of HCV obtained from patients infected with HCV genotypes 1b, 2a, or 2b. Administration of 10 µg/kg of human Peg-alfa twice a week for 2 weeks resulted in only a 0.53 log₁₀ decrease in the serum HCV RNA titre in HCV genotype 1b-infected mice (figure 1). In contrast, the same therapy resulted in 1.9 log₁₀ and 1.5 log₁₀ decreases in serum HCV RNA titres in mice with HCV genotypes 2a (p<0.05) and 2b (not significant), respectively. No decline in HCV RNA titre was observed in control mice infected with HCV genotype 1b during this 2-week period (figure 1). These results are consistent with the clinical observation that genotype 2 demonstrates a higher susceptibility to Peg-alfa treatment compared to HCV genotype 1.

Effects of BMS-605339, BMS-788329, or BMS-821095 on HCV genotype 1b in mice

We analysed the effect of DAA monotherapy on mice infected with HCV genotype 1b. Nine mice were injected with 10⁵ copies of HCV obtained from a patient infected with genotype 1b. Eight weeks after injection when stable viraemia had developed, mice were treated with BMS-605339 (NS3 PI) (figure 2A), BMS-788329 (NS5A RCI) (figure 2B) or BMS-821095 (NS5B




Figure 1 Antiviral effects of Peg-alfa treatment in mice. Mice were infected with hepatitis C virus (HCV) genotypes 1b (n=3), 2a (n=4) or 2b (n=4), then treated with 10 µg/kg of Peg-alfa twice per week for 2 weeks. HCV-infected mice without treatment (n=3) were also analysed (control). Mice serum HCV RNA titres were measured at the indicated times. Data are presented as mean±SD.

site I inhibitor) (figure 2C) for 4 weeks. Although all BMS-605339 and BMS-788329-treated mice showed an initial reduction of serum HCV RNA titres, all later showed rebound during treatment. Nucleotide analysis by direct sequencing revealed the emergence of a mutation coding for D168E in the NS3 region (NS3 PI-resistant variant)²¹ in a BMS-605339-treated mouse (figure 2A), and a mutation coding for Y93H in the NS5A region (NS5A RCI-resistant variant)¹⁴ in a BMS-788329-treated mouse at week 4 of treatment (figure 2B). Almost all mice treated with BMS-821095 showed an initial reduction in serum HCV RNA titres, and also showed rebound with the emergence of mutations coding for P495A and P495S in the NS5B region (NS5B site I inhibitor-resistant variant)²² at week 4 of treatment (figure 2C). HCV RNA titre reduction was not obvious in some mice treated with 30 mg/kg of BMS-821095 (figure 2C), suggesting that exposure of this inhibitor at 30 mg/kg dosing was not sufficient to suppress viral replication. Ultra-deep sequence analysis showed the development of a high prevalence of drug-resistant variants in mice sera in the NS3 PI, NS5A RCI-treated mice, and enrichment of pre-existing resistance variants in the NS5B NNI-treated mouse 4 weeks after the beginning of the treatment (figure 2D).

Combination treatment of BMS-788329 with either BMS-605339 or BMS-821095 in HCV genotype 1b mice

As monotherapies with either the NS3 PI, or the NS5A RCI or the NS5B NNI were unable to eradicate HCV RNA due to the emergent resistance variants, we analysed the effects of combining the NS5A RCI with either the NS3 PI or NS5B NNI. Mice infected with HCV genotype 1b (two mice per combination group) were treated with 10 mg/kg of BMS-788329 and either 75 mg/kg twice daily of BMS-605339 or 100 mg/kg of BMS-821095 for 4 weeks. In all mice, HCV RNA became negative by nested PCR 1 week after the beginning of combination therapy and remained undetectable after cessation of treatment (figure 3A,B). Elimination of the virus was assumed as HCV RNA was undetectable by nested PCR in mice livers treated with BMS-788329 and either BMS-605339 or BMS-821095 8 weeks (week 12) and 7 weeks (week 11) after cessation of therapy, respectively (figure 3C).

Table 1 In-vitro activity of BMS-605339, BMS-788329 and BMS-821095 in HCV replicon assays

Genotype (strain)	IC ₅₀ (nM)		
	BMS-605339	BMS-788329	BMS-821095
1b (Con 1)	3.5±0.8	0.012±0.005	3.8±0.6
2a (JFH-1)	81±27	0.014±0.007	365±266

Data are represented as means±SD from at least three independent experiments. HCV, hepatitis C virus. ##




Figure 2 Antiviral effects of BMS-605339, BMS-788329 or BMS-821095 monotherapy in mice infected with hepatitis C virus (HCV) genotype 1b. Mice were injected intravenously with 10^5 copies of HCV genotype 1b. Eight weeks after HCV infection, mice were treated with the indicated concentrations of BMS-605339 (A), BMS-788329 (B) or BMS-821095 (C) for 4 weeks. Serum samples were obtained at the indicated times, and HCV RNA titre and nucleotide and amino acid (aa) sequences were analysed. HCV-infected mice without treatment were also analysed (control). The horizontal dotted line indicates the HCV RNA titre detection limit (3 log copies/ml). (D) The aa frequencies in the BMS-605339 (top), BMS-788329 (middle bottom) or BMS-821095 (bottom) treated mice by ultra-deep sequencing before treatment and at 4 weeks are shown.

Combination treatment of BMS-788329 with either BMS-605339 or BMS-821095 in HCV genotype 2 mice

We analysed the effect of DAA combination therapies on mice infected with HCV genotypes 2a and 2b. In contrast to mice with genotype 1b, mice with genotypes 2a or 2b failed to respond to 4 weeks of treatment with BMS-788329 and BMS-605339 (figure 4A,B). Although the combination of BMS-788329 with BMS-821095 revealed no detectable viral load decline at the time points examined in genotype 2a mice, viral load reductions were detected in genotype 2b mice.

Sequence analysis revealed no emergence of resistance variants in the NS3, NS5A or NS5B regions before and 4 weeks after the end of each of these combination treatments, suggesting insufficient drug selection pressure (data not shown).

DISCUSSION

DAA-only therapy may offer a promising option to eradicate HCV without incurring the severe side effects of Peg-alfa. However, the emergence of drug-resistant variants is expected for all DAA²¹ and has already been observed in combination




Figure 3 Antiviral effects of NS5A replication complex inhibitor combinations with either an NS3 protease inhibitor or an NS5B inhibitor in mice infected with hepatitis C virus (HCV) genotype 1b. The four mice were treated with 10 mg/kg of BMS-788329 and either 75 mg/kg twice daily of BMS-605339 (A) or 100 mg/kg of BMS-821095 (B) for 4 weeks (closed circles). Mice without treatment were also analysed (open circles). Serum samples were obtained at the indicated times, and HCV RNA titres were measured. The horizontal dotted line indicates the HCV RNA titre detection limit (3 log copies/ml). (C) Nested PCR of HCV RNA, human serum albumin and GAPDH in mouse livers. Livers from mice treated with BMS-788329 and either BMS-605339 (lane 2) or BMS-821095 (lane 3) were obtained. Mouse livers with (lane 1) or without (lane 4) HCV infection were also analysed.

therapies with two DAA.^{5 23 24} If the exposure of the drugs can be safely increased, as we recently reported for a two-drug combination administered to human hepatocyte chimeric mice,¹² eradication of virus is still possible. In this study, we tested the ability of different two-DAA combination therapies to eradicate HCV. Although DAA monotherapies resulted in a viral breakthrough due to the development of a high prevalence of drug-resistant variants (figure 2A–D), DAA combination therapies with the NS5A RCI and either the NS3 PI or NS5B NNI were shown to eradicate virus successfully from HCV genotype 1b-infected mice with only 4 weeks of treatment (figure 3). These two-DAA combination treatments resulted in more rapid, robust declines within the first week of treatment when compared with the suboptimal antiviral responses from each of their respective monotherapies. Furthermore, regimens containing NS5A RCI appeared equally effective in treating mice chronically infected with hepatitis C genotype 1b.

In contrast to the rapid decrease in HCV RNA in mice infected with HCV genotype 1b, HCV genotype 2a and 2b-infected mice either did not respond or responded poorly to treatment with the NS5A RCI combined with either the NS3 PI or NS5B NNI (figure 4A,B). In this study, NS3 PI and NS5B NNI IC₅₀ values against genotype 1b were markedly more potent than against genotype 2a in cell culture systems (table 1). These findings are consistent with previous experimental results that reported reduced activity of these drug classes against genotype 2.^{25–28} In clinical trials, telaprevir monotherapy was found to result in a rapid decrease in serum HCV RNA levels in patients infected with HCV genotype 2; however, another protease inhibitor, BILN-2061, was less effective in patients with HCV genotype 2 compared to genotype 1.²⁹ Sequence analysis revealed a pre-existing A156G variant in the NS3 region, a L31M variant in the NS5A region and a I482L variant in the NS5B region in both HCV genotypes 2a and 2b infecting strains used in this study (data not shown). These NS3-A156G and NS5A-L31M variants confer resistance to inhibitors with similar chemical structures to BMS-605339 and BMS-788329, respectively, in genotype 2a replicon cell culture assays.^{30–32} Although BMS-788329 was very potent against the genotype-2a JFH-1 replicon (IC₅₀ 0.014 nM; table 1), its activity was significantly less against other genotype 2a and 2b viruses, such as genotype 2a HC-J6CF. The loss in potency observed in these viruses is not surprising because these viruses have a methionine at NS5A amino acid residue 31. The IC₅₀ of a genotype 2a hybrid replicon containing HC-J6CF NS5A with L31M substitution is approximately 10 nM (data not shown). The minimal antiviral response in mice infected with genotypes 2a and 2b receiving treatments containing BMS-788329 with either BMS-605339 or BMS-821095 can therefore be explained by pre-existing NS3, NS5A and NS5B resistance variants. Nevertheless, it is possible that mice infected with wild-type genotype 2 viruses and subsequently treated with higher doses of each of these DAA in dual or even triple combination therapy may have resulted in more robust reductions in viral load. The human hepatocyte chimeric mouse model offers a viable approach for identifying effective DAA-only combinations that not only act against HCV genotype 1 but against all HCV genotypes.

In summary, we demonstrated that an NS5A RCI can be effectively combined with different inhibitor classes to cure human hepatocyte chimeric mice infected with HCV genotype 1b after 4 weeks of treatment. However, these treatment combinations were not effective against HCV genotype 2. Oral combinations incorporating an NS5A RCI might offer Peg-alfa-free treatment options for genotype 1b chronic hepatitis C patients.

Acknowledgements The authors would like thank Rie Akiyama and Yoko Matsumoto for their expert technical help, and Bristol-Myers Squibb Research and Development for providing BMS-605339, BMS-788329 and BMS-821095 and suggesting the experimental design.

Funding This study was supported in part by a grant-in-aid for scientific research from the Japanese Ministry of Labour, Health and Welfare.

Competing interests MG and FM are employees of Bristol-Myers Squibb. All other authors declare no competing interests.

Ethics approval The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki and was approved a priori by the institutional review committee. All animal protocols described in this study were performed in accordance with the guidelines of the local committee for animal experiments, and all animals received humane care.

Patient consent Obtained.




Figure 4 Antiviral effects of NS5A replication complex inhibitor combinations with either NS3 protease inhibitor or NS5B inhibitor in mice infected with hepatitis C virus (HCV) genotype 2. Each of the four HCV genotype 2a (A) or 2b (B) infected mice were treated with 10 mg/kg of BMS-788329 combined with either 75 mg/kg twice daily of BMS-605339 (left panel) or 100 mg/kg of BMS-821095 (right panel) for 4 weeks (closed circles). Mice without treatment were also analysed (open circles). Serum samples were obtained at the indicated times, and HCV RNA titres were measured. The horizontal dotted line indicates the HCV RNA titre detection limit (3 log copies/ml).

Provenance and review Not commissioned; externally peer reviewed.

REFERENCES

- Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. *Hepatology* 1990;**12**:671–5.
- Niederer C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. *Hepatology* 1998;**28**:1687–95.
- Lin C, Gates CA, Rao BG, et al. In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. *J Biol Chem* 2005;**280**:36784–91.
- Mo H, Lu L, Pilot-Matias T, et al. Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. *Antimicrob Agents Chemother* 2005;**49**:4305–14.
- Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. *Lancet* 2010;**376**:1467–75.
- Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. *Hepatology* 2012;**55**:742–8.
- Gane E. Future hepatitis C virus treatment: interferon-sparing combinations. *Liver Int* 2011;**31**(Suppl. 1):62–7.
- Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. *Gastroenterology* 2011;**141**:e881–9.
- Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. *Nat Med* 2001;**7**:927–33.
- Kneteman NM, Weiner AJ, O'Connell J, et al. Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application. *Hepatology* 2006;**43**:1346–53.
- Hiraga N, Imamura M, Tsuge M, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon. *FEBS Lett* 2007;**581**:1983–7.
- Ohara E, Hiraga N, Imamura M, et al. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. *J Hepatol* 2011;**54**:872–8.
- Don RH, Cox PT, Wainwright BJ, et al. 'Touchdown' PCR to circumvent spurious priming during gene amplification. *Nucleic Acids Res* 1991;**19**:4008.
- Fridell RA, Qiu D, Wang C, et al. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. *Antimicrob Agents Chemother* 2010;**54**:3641–50.
- McPhee F, Sheaffer AK, Friborg J, et al. Preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). *Antimicrob Agents Chemother* 2012;**56**:5387–96.
- Sheaffer AK, Lee MS, Hernandez D, et al. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates. *Antiviral Ther* 2011;**16**:705–18.
- Tateno C, Yoshizane Y, Saito N, et al. Near completely humanised liver in mice shows human-type metabolic responses to drugs. *Am J Pathol* 2004;**165**:901–12.
- Kato T, Matsumura T, Heller T, et al. Production of infectious hepatitis C virus of various genotypes in cell cultures. *J Virol* 2007;**81**:4405–11.
- Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* 2010;**26**:589–95.
- Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. *Nature* 2010;**465**:96–100.
- Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. *Gastroenterology* 2010;**138**:447–62.
- Kukolj G, McGibbon GA, McKercher G, et al. Binding site characterization and resistance to a class of non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase. *J Biol Chem* 2005;**280**:39260–7.
- McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. *N Engl J Med* 2009;**360**:1827–38.
- Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. *N Engl J Med* 2009;**360**:1839–50.

25. **Paulson MS**, Yang H, Shih IH, *et al.* Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus. *Antiviral Res* 2009;**83**:135–42.
26. **Imhof I**, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). *Hepatology* 2011;**53**:1090–9.
27. **Imhof I**, Simmonds P. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6. *J Virol* 2010;**84**:4597–610.
28. **Scheel TK**, Gottwein JM, Mikkelsen LS, *et al.* Recombinant HCV variants with NS5A from genotypes 1–7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. *Gastroenterology* 2011;**140**:1032–42.
29. **Reiser M**, Hinrichsen H, Benhamou Y, *et al.* Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C. *Hepatology* 2005;**41**:832–5.
30. **Lenz O**, Verbinen T, Lin TI, *et al.* In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. *Antimicrob Agents Chemother* 2010;**54**:1878–87.
31. **Cheng G**, Chan K, Yang H, *et al.* Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system. *Antimicrob Agents Chemother* 2011;**55**:2197–205.
32. **Delang L**, Vliegen I, Froeyen M, *et al.* Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication. *Antimicrob Agents Chemother* 2011;**55**:4103–13.